Douglas W. Challener

1.3k total citations
59 papers, 604 citations indexed

About

Douglas W. Challener is a scholar working on Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Douglas W. Challener has authored 59 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 18 papers in Epidemiology and 12 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Douglas W. Challener's work include SARS-CoV-2 and COVID-19 Research (14 papers), COVID-19 Clinical Research Studies (10 papers) and SARS-CoV-2 detection and testing (9 papers). Douglas W. Challener is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (14 papers), COVID-19 Clinical Research Studies (10 papers) and SARS-CoV-2 detection and testing (9 papers). Douglas W. Challener collaborates with scholars based in United States, Norway and Saudi Arabia. Douglas W. Challener's co-authors include John C. O’Horo, M. Rizwan Sohail, Aditya Shah, Christina G. Rivera, Zelalem Temesgen, Fnu Shweta, Kelly M. Pennington, John D. Zeuli, Zachary A. Yetmar and Larry J. Prokop and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.

In The Last Decade

Douglas W. Challener

56 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas W. Challener United States 13 328 233 89 82 81 59 604
Fotinie Ntziora Greece 16 783 2.4× 642 2.8× 29 0.3× 141 1.7× 17 0.2× 33 1.2k
Anna Maria Peri Italy 15 177 0.5× 307 1.3× 27 0.3× 101 1.2× 40 0.5× 36 883
Muralidhar Varma India 12 326 1.0× 149 0.6× 23 0.3× 77 0.9× 8 0.1× 108 739
Soledad Reyes Spain 14 104 0.3× 551 2.4× 80 0.9× 43 0.5× 101 1.2× 29 778
Sirous Jafari Iran 13 218 0.7× 245 1.1× 91 1.0× 48 0.6× 13 0.2× 58 598
Fanny Vuotto France 10 451 1.4× 205 0.9× 13 0.1× 31 0.4× 7 0.1× 37 717
Fulvia Mazzaferri Italy 13 263 0.8× 191 0.8× 12 0.1× 30 0.4× 15 0.2× 24 633
Christopher Gilpin Switzerland 18 344 1.0× 345 1.5× 84 0.9× 127 1.5× 75 0.9× 30 622
David Mushatt United States 13 298 0.9× 260 1.1× 32 0.4× 56 0.7× 8 0.1× 30 559
Daniel Genné Switzerland 15 182 0.6× 511 2.2× 13 0.1× 132 1.6× 38 0.5× 53 929

Countries citing papers authored by Douglas W. Challener

Since Specialization
Citations

This map shows the geographic impact of Douglas W. Challener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas W. Challener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas W. Challener more than expected).

Fields of papers citing papers by Douglas W. Challener

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas W. Challener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas W. Challener. The network helps show where Douglas W. Challener may publish in the future.

Co-authorship network of co-authors of Douglas W. Challener

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas W. Challener. A scholar is included among the top collaborators of Douglas W. Challener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas W. Challener. Douglas W. Challener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McHugh, Jack, Douglas W. Challener, & Hussam Tabaja. (2025). Change of Heart: Can Artificial Intelligence Transform Infective Endocarditis Management?. Pathogens. 14(4). 371–371. 2 indexed citations
2.
Challener, Douglas W., Andrew Wen, Jungwei Fan, et al.. (2025). Flesch-Kincaid Grade Level Readability Scores to Evaluate Readability of Clinical Documentation During an Electronic Health Record Transition. PubMed. 1(1). VBWY7913–VBWY7913.
3.
4.
Yetmar, Zachary A., Supavit Chesdachai, Madiha Fida, et al.. (2025). Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes. Clinical Infectious Diseases. 82(3). 539–547. 1 indexed citations
5.
6.
Yetmar, Zachary A., Ryan B. Khodadadi, Supavit Chesdachai, et al.. (2024). Epidemiology, Timing, and Secondary Prophylaxis of Recurrent Nocardiosis. Open Forum Infectious Diseases. 11(4). ofae122–ofae122. 6 indexed citations
7.
Challener, Douglas W., et al.. (2024). Evaluation of germicidal ultraviolet-C disinfection in a real-world outpatient health care environment. American Journal of Infection Control. 52(9). 1030–1034. 2 indexed citations
8.
Ranganath, Nischal, Douglas W. Challener, Ryan W. Stevens, et al.. (2023). Leptotrichia Bacteremia: 10-Year Retrospective Clinical Analysis and Antimicrobial Susceptibility Profiles. Journal of Clinical Microbiology. 61(2). e0173322–e0173322. 4 indexed citations
9.
Yetmar, Zachary A., Supavit Chesdachai, Byron H. Smith, et al.. (2023). Risk factors and prophylaxis for nocardiosis in solid organ transplant recipients: A nested case‐control study. Clinical Transplantation. 37(9). e15016–e15016. 9 indexed citations
10.
Pawlowski, Colin, Eli Silvert, John C. O’Horo, et al.. (2022). SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes. PNAS Nexus. 1(3). pgac071–pgac071. 11 indexed citations
11.
Ranganath, Nischal, John C. O’Horo, Douglas W. Challener, et al.. (2022). Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases. 76(3). e537–e539. 45 indexed citations
12.
O’Horo, John C., Douglas W. Challener, Ryan J. Anderson, et al.. (2022). Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Mayo Clinic Proceedings. 97(5). 943–950. 3 indexed citations
13.
Shah, Aditya, Douglas W. Challener, John C. O’Horo, & Andrew D. Badley. (2021). Vaccination Safety. Mayo Clinic Proceedings. 96(7). 1712–1713. 1 indexed citations
14.
O’Horo, John C., Douglas W. Challener, Leigh L. Speicher, et al.. (2021). Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clinic Proceedings. 97(2). 327–332. 16 indexed citations
15.
Challener, Douglas W., Aditya Shah, John C. O’Horo, et al.. (2020). Low Utility of Repeat Real-Time PCR Testing for SARS-CoV-2 in Clinical Specimens. Mayo Clinic Proceedings. 95(9). 1942–1945. 6 indexed citations
16.
Shah, Aditya, Aaron J. Tande, Douglas W. Challener, et al.. (2020). Diagnostic Stewardship: An Essential Element in a Rapidly Evolving COVID-19 Pandemic. Mayo Clinic Proceedings. 95(9). S17–S19. 5 indexed citations
17.
Tande, Aaron J., Douglas W. Challener, Aditya Shah, John C. O’Horo, & Elena Beam. (2020). Community-Based Drive-Through and Walk-Through Testing Centers. Mayo Clinic Proceedings. 95(9). S20–S22. 4 indexed citations
18.
Shah, Aditya, Douglas W. Challener, Aaron J. Tande, et al.. (2020). Drive-Through Testing. Mayo Clinic Proceedings. 95(7). 1420–1425. 26 indexed citations
19.
Challener, Douglas W., Jasmine R Marcelin, Sue L. Visscher, & Larry M. Baddour. (2017). Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study. Hospital Practice. 45(5). 196–200. 10 indexed citations
20.
Challener, Douglas W. & Omar Abu Saleh. (2017). A Traveler's Unwanted Souvenir. The American Journal of Medicine. 131(4). e137–e138. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fotinie Ntziora Breakdown of academic impact, for papers by Anna Maria Peri Breakdown of academic impact, for papers by Muralidhar Varma Breakdown of academic impact, for papers by Soledad Reyes Breakdown of academic impact, for papers by Sirous Jafari Breakdown of academic impact, for papers by Fanny Vuotto Breakdown of academic impact, for papers by Fulvia Mazzaferri Breakdown of academic impact, for papers by Christopher Gilpin Breakdown of academic impact, for papers by David Mushatt Breakdown of academic impact, for papers by Daniel Genné
Rankless by CCL
2026